(Finance) – Labomaran Italian nutraceutical company listed on the Euronext Growth Milan market, closed the first half with consolidated revenues of 41.8 million euros, with a increase of 36.9% compared to the figure achieved in the same period of 2021 (30.5 million euros).
Consolidated revenues include, in addition to the values of Labomar Spa and Entreprises ImportFab, the turnover of the companies acquired in the second half of 2021, namely the Welcare Group and Labiotre. On a like-for-like basis, revenues would have amounted to 34.1 million euros, with an increase of almost 12 percentage points compared to 2021.
This growth is supported in particular by the Parent Company which saw a recovery in sales of products belonging to the probiotics and cough & cold categories, which had particularly suffered in 2021 due to the Covid-19 pandemic. There was also an increase in turnover of the main international key accounts and an increase in the portfolio of new products launched in the last 12 months.